↓ Skip to main content

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Overview of attention for article published in Journal of Hematology & Oncology, March 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#46 of 1,121)
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

blogs
2 blogs
twitter
6 tweeters
patent
2 patents
wikipedia
4 Wikipedia pages

Citations

dimensions_citation
153 Dimensions

Readers on

mendeley
171 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Published in
Journal of Hematology & Oncology, March 2016
DOI 10.1186/s13045-016-0250-9
Pubmed ID
Authors

Jingjing Wu, Mingzhi Zhang, Delong Liu

Abstract

More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 171 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 <1%
Unknown 170 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 29 17%
Student > Ph. D. Student 27 16%
Student > Bachelor 26 15%
Student > Master 17 10%
Other 13 8%
Other 28 16%
Unknown 31 18%
Readers by discipline Count As %
Medicine and Dentistry 37 22%
Chemistry 31 18%
Biochemistry, Genetics and Molecular Biology 23 13%
Pharmacology, Toxicology and Pharmaceutical Science 20 12%
Agricultural and Biological Sciences 12 7%
Other 13 8%
Unknown 35 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2022.
All research outputs
#1,195,698
of 21,742,867 outputs
Outputs from Journal of Hematology & Oncology
#46
of 1,121 outputs
Outputs of similar age
#21,666
of 280,086 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 1 outputs
Altmetric has tracked 21,742,867 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,121 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,086 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them